Android app on Google Play

Aegerion Pharmaceuticals (AEGR) Run Up Not Over; PT Doubled at Needham & Company

July 22, 2013 7:30 AM EDT Send to a Friend
Get Alerts AEGR Hot Sheet
Price: $30.07 --0%

Rating Summary:
    14 Buy, 1 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 16 | Down: 24 | New: 8
Trade AEGR Now!
Join SI Premium – FREE
Needham & Company analyst Chad Messer doubled his price target on Buy-rated Aegerion Pharmaceuticals (NASDAQ: AEGR) from $50 to $100, saying the earnings potential from Juxtapid more than justifies the stock move.

Messer comments, "AEGR shares have returned >200% since Juxtapid received approval last December. While many investors may feel like they have missed out on the run-up, we put Aegerion's current $2.3 billion market capitalization into context with how we see Juxtapid's earnings potential. Assuming just 17% of our estimated 14,000 eligible patients are on treatment by 2018, we forecast worldwide Juxtapid sales of $590MM, equating to AEGR EPS of $7.28. Applying a 30X multiple, which we believe is conservative vs peer companies, and a 25% discount rate implies a 12-month price target of $100."

For an analyst ratings summary and ratings history on Aegerion Pharmaceuticals click here. For more ratings news on Aegerion Pharmaceuticals click here.

Shares of Aegerion Pharmaceuticals closed at $78.59 yesterday.




You May Also Be Interested In


Related Categories

Analyst Comments, Analyst PT Change, Hot Comments

Related Entities

Needham & Company, Earnings

Add Your Comment